Foghorn Therapeutics Inc. (FHTX)
| Market Cap | 243.08M -0.4% |
| Revenue (ttm) | 28.22M +20.1% |
| Net Income | -75.32M |
| EPS | -1.17 |
| Shares Out | 58.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 73,001 |
| Open | 4.220 |
| Previous Close | 4.240 |
| Day's Range | 4.130 - 4.343 |
| 52-Week Range | 3.270 - 6.950 |
| Beta | 2.97 |
| Analysts | Strong Buy |
| Price Target | 11.29 (+172.71%) |
| Earnings Date | May 7, 2026 |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leuk... [Read more]
Financial Performance
In 2025, Foghorn Therapeutics's revenue was $30.91 million, an increase of 36.75% compared to the previous year's $22.60 million. Losses were -$74.28 million, -14.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price target is $11.29, which is an increase of 172.71% from the latest price.
News
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)
Reports Q1 revenue $3.27M, consensus $7.94M. “Our lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA...
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memor...
Foghorn Therapeutics presents new preclinical data for FHD-909
Foghorn Therapeutics (FHTX) presented new preclinical data for Selective SMARCA2 inhibitor FHD-909 showing complete and durable tumor regression together with anti-tumor immune memory following combin...
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Foghorn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The pipeline features advanced protein degrader programs in oncology, with key assets progressing toward IND-enabling studies and a major partnered SMARCA2 program in dose escalation. Financial strength was bolstered by a recent $50 million offering, supporting ongoing R&D and clinical milestones.
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics appoints Maynard as Chief Financial Officer
Foghorn Therapeutics (FHTX) announced that Ryan Maynard will join the company as Chief Financial Officer, CFO, on February 23, 2026. Maynard joins Foghorn with over 25 years of executive experience…
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
Jefferies lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $12 from $14 and keeps a Buy rating on the shares while taking over lead coverage of the stock.
Foghorn Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The discussion highlighted the scientific rationale for targeting chromatin regulatory complexes in cancer, detailed progress on SMARCA2 (in partnership with Lilly) and wholly owned CBP/EP300 programs, and outlined clinical and preclinical advances. Key updates and expansion decisions are expected later this year.
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026
Foghorn Therapeutics initiated with a Buy at BTIG
BTIG initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $11 price target The firm says Foghorn is a clinical-stage biopharmaceutical company developing novel inhibitors and degrad...
Foghorn Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing a precision oncology pipeline focused on chromatin regulation, with its lead 909 program in partnership with Lilly targeting SMARCA2 in non-small cell lung cancer. Strong enrollment and promising preclinical data support a potential move to first-line settings and pipeline expansion in 2024.
Foghorn Therapeutics initiated with a Buy at Stifel
Stifel initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target. Lead asset FHD-909, partnered 50/50 with Eli Lilly (LLY), expects initial data in 2026, notes…
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Transcript: Jefferies London Healthcare Conference 2025
A major partnership with Eli Lilly drives the SMARCA2 program, with a key dose expansion decision expected in H1 2026. Proprietary assets targeting chromatin regulators are advancing toward IND, and the company is well-funded into early 2028.
Foghorn Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Chromatin regulation is a key focus, with selective targeting of SMARCA2 in cancers with SMARCA4 loss showing strong preclinical and early clinical promise. The pipeline includes advanced CBP and EP300 programs and a novel ARID1B degrader, all aiming for improved selectivity and tolerability.
Foghorn Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
Reports Q3 revenue $8.153M, consensus $6.2M. “This quarter marked continued execution across our portfolio, reinforcing our leadership in developing novel precision therapies with broad applicability ...
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degr...